Pharma Journalist -

Xeris Pharmaceuticals, Inc. a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug…
Read More...

NGM Biopharmaceuticals, Inc. a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced the expansion of its oncology portfolio…
Read More...

Akron Biotechnology announced it has signed an agreement with Synairgen plc  for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic…
Read More...

Edesa Biotech, Inc. a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3…
Read More...

Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, announced that…
Read More...

SMi Reports: The 2021 conference is now a virtual conference: Online access only. Explore Innovations in technologies and applications of RNA-based medicine. Join us in February…
Read More...

SMi Reports: The 2021 conference is now a virtual conference: Online access only. Discover key progressive insights: At the forefront of pioneering developments at PFS 2021. In light…
Read More...

AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic…
Read More...

Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund,  announced that they have received approval from the Drug Control General of…
Read More...

Orchard Therapeutics, a global gene therapy leader, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a…
Read More...